Document Detail


Hemodynamic and neuroendocrine responses to acute and chronic alpha-adrenergic blockade with prazosin and phenoxybenzamine.
MedLine Citation:
PMID:  6129077     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We investigated the relevance of the selective alpha 1-adrenergic receptor blockade produced by prazosin to its blood pressure-lowering efficacy in man. The hemodynamic and neuroendocrine responses to the acute and chronic oral administration of prazosin and phenoxybenzamine were compared in a randomized, double-blind, placebo-controlled, crossover study of 11 patients with essential hypertension. These responses were also evaluated during lower body negative pressure and dynamic bicycle exercise, which produce potent but diversified activation of the sympathetic nervous system. In the acute studies, arterial blood pressure decreased to similar levels with prazosin or phenoxybenzamine; however, hemodynamic and neuroendocrine responses differed both before and during sympathetic nervous system activation. Prazosin lowered arterial blood pressure by reducing total peripheral resistance (p less than 0.05). In contrast, phenoxybenzamine produced a modest reduction in cardiac output (8%, p less than 0.05) with little change in total peripheral resistance, forearm vascular resistance or forearm blood flow. Additionally, plasma norepinephrine concentration and heart rate rose to significantly higher levels with prazosin (p less than 0.02) than with phenoxybenzamine, a difference that was most evident with lower body negative pressure or dynamic exercise. Baroreceptor control of arterial pressure homeostasis was preserved with both agents, except during marked degrees of cardiovascular stress. With chronic therapy, the circulatory responses adapted to the alpha-adrenergic antagonists, and both drugs produced similar hemodynamic and neuroendocrine profiles. The differences with acute administration may be the result of a more rapid onset of action and a more marked degree of alpha-adrenergic blockage with prazosin than with phenoxybenzamine therapy, rather than to any difference in their alpha 1- and alpha 2-adrenergic receptor blocking properties. Moreover, the findings of the present study suggest that the prejunctional alpha 2-receptor, autoinhibitory to sympathetic neuronal norepinephrine release, is of no functional significance in patients with essential hypertension.
Authors:
J Mulvihill-Wilson; F A Gaffney; W A Pettinger; C G Blomqvist; S Anderson; R M Graham
Related Documents :
6279217 - The role of presynaptic alpha-adrenoceptors in the regulation of blood pressure in the ...
23591827 - A novel stress echocardiography pattern for myocardial bridge with invasive structural ...
6499237 - Blood pressure responses to prolonged infusions of adrenaline and noradrenaline in cons...
2312767 - The effects of enalapril on urinary protein excretion in patients with idiopathic membr...
18186347 - Calibration of an in situ membrane inlet mass spectrometer for measurements of dissolve...
3498157 - Regional vasodilator actions of calcitonin gene-related peptide in conscious shr.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Circulation     Volume:  67     ISSN:  0009-7322     ISO Abbreviation:  Circulation     Publication Date:  1983 Feb 
Date Detail:
Created Date:  1983-02-25     Completed Date:  1983-02-25     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  383-93     Citation Subset:  AIM; IM; S    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic alpha-Antagonists / administration & dosage*,  therapeutic use
Adult
Double-Blind Method
Female
Hemodynamics*
Humans
Hypertension / blood,  drug therapy,  physiopathology*
Lower Body Negative Pressure
Male
Middle Aged
Norepinephrine / blood*
Physical Exertion
Prazosin / administration & dosage*
Quinazolines / administration & dosage*
Grant Support
ID/Acronym/Agency:
5-R01-HL24480/HL/NHLBI NIH HHS; 5-T32-GM07247/GM/NIGMS NIH HHS
Chemical
Reg. No./Substance:
0/Adrenergic alpha-Antagonists; 0/Quinazolines; 19216-56-9/Prazosin; 51-41-2/Norepinephrine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Right ventricular performance during increased afterload impaired by hypercapnic acidosis in conscio...
Next Document:  Soluble forms of gamma-glutamyltransferase in human adult liver, fetal liver, and primary hepatoma c...